Integrin inhibitors reaching the clinic.
| Data(s) |
2007
|
|---|---|
| Identificador |
http://serval.unil.ch/?id=serval:BIB_D04523CA13A0 isbn:1527-7755[electronic] pmid:17470853 doi:10.1200/JCO.2006.09.8376 isiid:000246299500001 |
| Idioma(s) |
en |
| Fonte |
Journal of Clinical Oncology, vol. 25, no. 13, pp. 1637-1638 |
| Palavras-Chave | #Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Growth Substances/physiology; Humans; Integrins/antagonists & inhibitors; Neoplasms/drug therapy; Snake Venoms/adverse effects; Snake Venoms/therapeutic use; Treatment Outcome |
| Tipo |
info:eu-repo/semantics/article article |
